Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.67 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | DRD3 | P35462 | 5/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17912992 | 0.81 | PKM (0.79) | PKMROCK2DRD2DRD3HDAC1 | |
| SCHEMBL19643787 | 0.77 | SNCA (0.39) | PKMCMA1SIGMAR1ALDH1A1KDM4E | |
| SCHEMBL17912900 | 0.77 | TP53 (0.48) | PKMROCK2HDAC1CMA1MTNR1A | |
| SCHEMBL26095917 | 0.77 | CMA1 (0.43) | PKMHDAC1CMA1ALDH1A1KDM4E | |
| SCHEMBL19643226 | 0.74 | ROCK2 (0.59) | ROCK2 | |
| SCHEMBL16915064 | 0.74 | PKM (0.65) | PKMROCK2DRD2DRD3HDAC1 | |
| SCHEMBL17912948 | 0.74 | PKM (0.68) | PKMROCK2DRD2DRD3HDAC1 | |
| SCHEMBL16915088 | 0.74 | PKM (0.67) | PKMROCK2 | |
| SCHEMBL17913016 | 0.73 | PKM (0.66) | PKMROCK2DRD2DRD3HDAC1 | |
| SCHEMBL8913255 | 0.73 | HDAC1 (0.67) | PKMROCK2HDAC1RAB9ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406426-B | Cyclic ureas as ROCK inhibitors | 百时美施贵宝公司 | 2020-11-20 | — | — | CN | disclosed |
| EP-3242873-B1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3242873-B1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10123993-B2 | Cyclic ureas as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180000788-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-01-04 | — | — | US | disclosed |
| US-20180000788-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-01-04 | — | — | US | disclosed |
| EP-3242873-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2017-11-15 | — | — | EP | disclosed |
| WO-2016112236-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | WO | disclosed |
| WO-2016112236-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123993-B2 | Cyclic ureas as inhibitors of rock | MYLK, ROCK1, UACA | PKM 1485/4885ROCK2 4/4885DRD2 4833/4885 |
| US-20180000788-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | MYLK, ROCK1, UACA | PKM 1485/4885ROCK2 4/4885DRD2 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.